Top 5 Things I Learned from Alpha IVF’s 2024 AGM

As a long time shareholder (perhaps not so long) of Alpha IVF Group Berhad (Alpha IVF), the Company’s recent Annual General Meeting (AGM) provided a comprehensive overview of the company’s strategic directions, financial performance, and growth plans.

Here are the top 5 key takeaways from the AGM.

Alpha IVF recorded a revenue increase of 21.9% compared to the previous financial year, reaching a total of RM167.6 million, and Oocyte Pick-Up (OPU) increased by 14.6% to 3,093 in FYE 2024. This growth was driven by higher demand from local and foreign, particularly in IVF treatments, indicating strong market demand and successful marketing strategies.

Profit after tax and Minority Interest (PATMI) remains stable at RM52.9 million, impacted by the one-off listing expenses in the current financial year.

Alpha IVF have a dividend policy of at least 60% of the PATMI for each financial year, and in FYE2024, the company paid a total of 0.45 sen per share of RM21.9 million in terms of dividend to reward shareholders.

The company was listed on 22 March 2024, raising RM116.6 million in total funds, and secured the crown of the largest ACE Market IPO ever on Bursa Malaysia with a market capitalisation of RM1.6 billion. Today, at the time of writing, the market cap of Alpha IVF is very close to RM1.7 billion, rendering the IPO highly successful one.

In the AGM, the company also mentioned that Alhaya, the 51.0% owned specialists centre of Alpha IVF, is expected to cater for the largely untapped Muslim market, both domestically and internationally. For those who do not know, Alhaya is situated in KPJ Damansara Specialist Hospital 2, and this would allow Alpha IVF to tap into the strong stream of potential clients by working closely with KPJ.

Currently, Alpha IVF had 4 IVF centres in operation and 1 sales representative office in China that has begun operation, with the ambitious plan to have flagship centres in Manila, Philippines and Indonesia, one of the largest streams of foreign client for Alpha IVF, the company has a long runaway in terms of future growth to come.

In conclusion, I’m satisfied on the results and presentation of Alpha IVF, and of course on the dividends too. Let’s continue to observe the financial performance of the company to come.